Jason Keyes Purchases 700 Shares of BlossomHill Therapeutics (NASDAQ:BLSM) Stock

Key Points

  • Director Bihua Chen purchased 312,500 BlossomHill Therapeutics shares at $16 each, investing a total of $5 million.
  • The transaction increased Chen’s ownership by 9.47% to 3,614,034 shares, valued at approximately $57.8 million, according to an SEC filing.
  • BlossomHill shares opened at $15.99 and were down 0.1%, trading within a 12-month range of $15.25 to $17.25.

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM - Get Free Report) CFO Jason Keyes bought 700 shares of the company's stock in a transaction dated Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, with a total value of $11,200.00. Following the acquisition, the chief financial officer directly owned 700 shares of the company's stock, valued at approximately $11,200. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BlossomHill Therapeutics Stock Down 0.1%

Shares of NASDAQ BLSM opened at $15.99 on Tuesday. BlossomHill Therapeutics, Inc. has a 52 week low of $15.25 and a 52 week high of $17.25.

See Also

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at BlossomHill Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for BlossomHill Therapeutics and related companies.
From Our Partners
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles